The U.S. Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for ...

StockNews.com lowered shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from a buy rating to a hold rating in a research note published on Monday morning. Several other analysts have also ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price ...